While continuing in vitro and preclinical studies to support its primary therapeutic programs, HSC and oncology, Histogen has been able to explore other indications and produce proof-of-concept data that supports further development in these areas. Such applications include medical device coatings, tissue filler for various indications, and a post-procedure application for advanced healing.
- Medical device coatings: when used as a coating, the biomaterial has been shown to reduce fibrous encapsulation and increase biocompatibility. This application can be utilized in various fields of the device industry including hernia repair, pelvic floor repair, stents, breast implants, and dental implants.
- Tissue filler: as a soft tissue and hard tissue filler, the ECM is expected to provide a scaffold for tissue in growth. The material has potential for soft tissue augmentation (ie. dermal filler or post-tumor resection) and as a bone filler that promotes osteoinduction.
- Post-procedure application: as an additive to a topical formulation, the CCM has demonstrated improved healing benefits following laser procedures. This material can be further explored in other wound healing applications that range from cosmetic surgery to more advanced healing indications such as diabetic foot ulcers.
Histogen seeks to partner and out-license its biomaterials for further development and commercialization. For more information, please visit our Business Development page.